

- Alfano D., Franco P., Stoppelli M.P. Modulation of Cellular Function by the Urokinase Receptor Signalling: A Mechanistic View. *Front. Cell Dev. Biol.* 2022;10:818616. doi: 10.3389/fcell.2022.818616.
- Ali, A., Ansari, M. A., Patel, S., & Srivastava, V. (2020). Urokinase type plasminogen activator expression and its correlation with angiogenesis and lymph node metastasis in breast cancer. *MOJ Surgery*, 8(3), 53–59. <https://doi.org/10.15406/mojs.2020.08.00172>
- American Cancer Society. (2022). Breast cancer facts and figures 2022-2024. In *American Cancer Society* (pp. 1–44). <https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/breast-cancer-facts-and-figures/2022-2024-breast-cancer-fact-figures-acf.pdf?utm>
- Andreasen PA, Kjøller L, Christensen L, Duffy MJ. The urokinase type plasminogen activator system in cancer metastasis: a review. *Int J Cancer*. 1997;72:1–22.
- Bakkour, AM., Surriah, MH., Al-Imari, ANK. and Al-Asadi, RRJ. (2019) ‘The predictors and the prognostic significance of axillary lymph nodes involvement in breast cancer’, *International Surgery Journal*, 6(5), pp. 1641–1645.
- Banys-Paluchowski, M., Witzel, I., Aktas, B., Fasching, P. A., Hartkopf, A., Janni, W., Kasimir-Bauer, S., Pantel, K., Schön, G., Rack, B., Riethdorf, S., Solomayer, E.-F., Fehm, T., & Müller, V. (2019). The prognostic relevance of urokinase-type plasminogen activator (uPA) in the blood of patients with metastatic breast cancer. *Scientific Reports*, 9(1), 2318. <https://doi.org/10.1038/s41598-018-37259-2>
- B Jackson, E., Gondara, L., Speers, C., Diocee, R., M Nichol, A., Lohrisch, C., & A Gelmon, K. (2023). Does age affect outcome with breast cancer? *The Breast*, 70, 25–31. <https://doi.org/10.1016/j.breast.2023.06.001>
- PERABOI. (2023). *Panduan Tatalaksana Kanker Payudara 2023* (Vol. 3). PERABOI.
- Blaisi F, Carmeliet P. uPAR: a versatile signalling orchestrator. *Nat Rev Mol Cell Biol*. 2002;3:932–43
- Cardoso, F. et al. (2020) ‘Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up’, *Annals of Oncology*, 31(12), pp. 1670–1692.
- Chaffer, C. L. & Weinberg, R. A. A perspective on cancer cell metastasis. 2011. *Science* 331, 1559–1564 .
- Chen, X. et al. (2017) ‘Prognostic significance of lymphovascular invasion in breast cancer: a systematic review and meta-analysis’, *Breast Cancer Research and Treatment*, 163(1), pp. 17–28.
- Deryugina EI, Quigley JP. Cell surface remodeling by plasmin: a new function for an old enzyme. *J Biomed Biotechnol*. 2012;5:642–59. [PMC free article] [PubMed] [Google Scholar]
- Davey, M. G., Hynes, S. O., Kerin, M. J., Miller, N., & Lowery, A. J. (2021). Ki-67 as a Prognostic Biomarker in Invasive Breast Cancer. *Cancers*, 13(17), 4455. <https://doi.org/10.3390/cancers13174455>
- DeVita, V.T., Lawrence, T.S. & Rosenberg, S.A. (eds.) (2022). *DeVita, Hellman, and Rosenberg’s Cancer: Principles & Practice of Oncology*. 12th ed. Philadelphia: Wolters Kluwer. ISBN 978-1975184742.

- Deluche, E., Venat-Bouvet, L., Lebon, S., Fermeaux, V., Mollard, J., Saidi, N., Jammet, I., Aubard, Y., & Tubiana-Mathieu, N. (2017). Assessment of Ki67 and uPA/PAI-1 expression in intermediate-risk early stage breast cancers. *BMC Cancer*, 17(1), 662. <https://doi.org/10.1186/s12885-017-3648-z>
- Devy L, Blacher S, Grignet-Debrus C, et al. The pro or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent. *FASEB J*. 2002;16:147–54. [PubMed] [Google Scholar]
- Donald Courtney, Matthew G, Brian M , Michael K, Karl S, Ray P, Carmel M. Lowery, Michael J. Breast cancer recurrence: factors impacting occurrence and survival. *Ir J Med Sci*. 2022; 191(6): 2501-2510.
- Dovnik, N. F., & Takac, I. (2017). Prognostic significance of uPA/PAI-1 level, HER2 status, and traditional histologic factors for survival in node-negative breast cancer patients. *Radiology and Oncology*, 51(1), 65–73. <https://doi.org/10.1515/raon-2016-0024>
- Duffy, M.J., McGowan, P.M., Harbeck, N., Thomssen, C. & Schmitt, M., 2014. uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies. *Breast Cancer Research*, 16(4), p.428. Available at: <https://doi.org/10.1186/s13058-014-0428-4>
- Dutta, S.; Ganguly, A.; Chatterjee, K.; Spada, S.; Mukherjee, S. Targets of Immune Escape Mechanisms in Cancer: Basis for Development and Evolution of Cancer Immune Checkpoint Inhibitors. *Biology* 2023, 12, 218.
- Elleson, K. M., Englander, K., Gallagher, J., Chintapally, N., Sun, W., Whiting, J., Mallory, M., Kiluk, J., Hoover, S., Khakpour, N., Czerniecki, B., Laronga, C., & Lee, M. C. (2023). Factors Predictive of Positive Lymph Nodes for Breast Cancer. *Current Oncology*, 30(12), 10351–10362. <https://doi.org/10.3390/curroncol30120754>
- Fan, J.-H., Zhang, S., Yang, H., Yi, Z.-B., Ouyang, Q.-C., Yan, M., Wang, X.-J., Hu, X.-C., Jiang, Z.-F., Huang, T., Tong, Z.-S., Wang, S.-S., Yin, Y.-M., Li, H., Yang, R.-X., Yang, H.-W., Teng, Y.-E., Sun, T., Cai, L., ... Qiao, Y.-L. (2023). Molecular subtypes predict the preferential site of distant metastasis in advanced breast cancer: a nationwide retrospective study. *Frontiers in Oncology*, 13, 01–12. <https://doi.org/10.3389/fonc.2023.978985>
- Ferraris GM, Sidenius N. Urokinase plasminogen activator receptor: a functional integrator of extracellular proteolysis, cell adhesion, and signal transduction. *Semin Thromb Hemost*. 2013;39:347–55.
- Gao, Y., Bado, I., Wang, H., Zhang, W., Rosen, J.M. & Zhang, X.H-F. (2019). Metastasis organotropism: redefining the congenial soil. *Developmental Cell*, 49(3), 375–391. <https://doi.org/10.1016/j.devcel.2019.04.012>
- García-Tejedor, Á. et al. (2019) ‘Accuracy of immunohistochemical markers for detection of lymphovascular invasion in breast cancer’, *Modern Pathology*, 32(7), pp. 1023–1032.
- Gouri, A., Dekaken, A., El Bairi, K., Aissaoui, A., Laabed, N., Chefrour, M., Ciccolini, J., Milano, G. & Benharkat, S. (2016) ‘Plasminogen Activator System and Breast Cancer: Potential Role in Therapy Decision Making and Precision Medicine’, *Biomarker Insights*, 11, pp. 105–111. doi: 10.4137/BMI.S33372. PMCID: PMC4993165. PMID: 27578963.
- Gehling, G. M., Alfaqih, M., Pruinelli, L., Starkweather, A., & Dungan, J. R. (2024). A systematic review of candidate genes and their relevant pathways for metastasis among adults diagnosed with breast cancer. *Breast Cancer Research*, 26(1), 165. <https://doi.org/10.1186/s13058-024-01914-6>

Garcia-Tejedor, A. et al. (2019) 'Accuracy of immunohistochemical markers for detection of lymphovascular invasion in breast cancer', *Modern Pathology*, 32(7), pp. 1023–1032.

Goldhirsch, A. et al. (2011) 'Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus', *Annals of Oncology*, 22(8), pp. 1736–1747.

Hamada, M., Varkoly, K.S., Riyadh, O., Beladi, R., Munuswamy-Ramanujam, G., Rawls, A., Wilson-Rawls, J., Chen, H., McFadden, G. & Lucas, A.R. (2024). Urokinase-Type Plasminogen Activator Receptor (uPAR) in Inflammation and Disease: A Unique Inflammatory Pathway Activator. *Biomedicines*, 12(6), 1167. <https://doi.org/10.3390/biomedicines12061167>.

Harel E.T., Drake P.M., Barfield R.M., Lui I., Farr-Jones S., Van't Veer L., Gartner Z.J., Green E.M., Lourenço A.L., Cheng Y., et al. Antibody-Drug Conjugates Targeting the Urokinase Receptor (uPAR) as a Possible Treatment of Aggressive Breast Cancer. *Antibodies*. 2019;8:54. doi: 10.3390/antib8040054.

Harvey N. Mayrovitz, P. (2022). *Breast Cancer* (Vol. 1).

Huang, C.C., Lin, Y.H., Kuo, C.F. & Wang, L.J. (2025) 'Treatment patterns and outcomes of young female early breast cancer (≤ 40 years) in Taiwan: A nationwide cancer registry study', *Breast Cancer Research and Treatment*, 184(2), pp. 321–332. doi:10.1007/s10549-025-06789

Inoue, S. & Osmond, D. G. Basement membrane of mouse bone marrow sinusoids shows distinctive structure and proteoglycan composition: a high resolution ultrastructural study.2001. *Anat. Rec.* 264, 294–304).

Inwald, E.C. et al. (2013) 'Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry', *Breast Cancer Research and Treatment*, 139(2), pp. 539–552.

Ismail, A.A., Menzel, P., Biebl, A., ... et al. (2021). The plasminogen–activator plasmin system in extracellular matrix remodelling and cancer progression. *Cellular Oncology*, 44(1), 1–20. doi:10.1007/s13402-020-00565-0

Jevrić, M., Matić, I. Z., Krivokuća, A., Đorđić Crnogorac, M., Besu, I., Damjanović, A., Branković-Magić, M., Milovanović, Z., Gavrilović, D., Susnjarić, S., Kisić Tepavčević, D., & Stanojković, T. (2019). Association of uPA and PAI-1 tumor levels and 4G/5G variants of PAI-1 gene with disease outcome in luminal HER2-negative node-negative breast cancer patients treated with adjuvant endocrine therapy. *BMC Cancer*, 19(1), 71. <https://doi.org/10.1186/s12885-018-5255-z>

Jia-Ju, L., Hong, G., Bo G., Yun, Z., Qing-Ling, L., Jiang, S., Jing-Jing, L., Jian, L (2018). Prognostic value of urokinase plasminogen activator system in non-small cell lung cancer: A systematic review and meta-analysis, 8(1): 127–132

Ji, H. et al. (2023) 'Lymph node metastasis in cancer progression: molecular mechanisms, clinical significance and therapeutic interventions', *Signal Transduction and Targeted Therapy*, 8, p. 367.

Jo M, Thomas KS, Somlo AV, Somlyo AP, Gonias SL. Cooperativity between the ras-ERK and Rho-Rho kinase pathway in urokinase-type plasminogen activator-stimulated cell migration. *J Biol Chem*. 2002;277:12479–85. [PubMed] [Google Scholar]

Jo M, Thomas KS, Marozkina N, et al. Dynamic assembly of the urokinase-type plasminogen activator signaling receptor complex determines the mitogenic activity of urokinase-type plasminogen activator. *J Biol Chem*. 2005;280:17449–57. [PubMed] [Google Scholar]

- Kim, E. Y., Do, S.-I., Hyun, K., Park, Y. L., Kim, D.-H., Chae, S. W., Sohn, J. H., & Park, C. H. (2016). High Expression of Urokinase-Type Plasminogen Activator Is Associated with Lymph Node Metastasis of Invasive Ductal Carcinoma of the Breast. *Journal of Breast Cancer*, 19(2), 156. <https://doi.org/10.4048/jbc.2016.19.2.156>
- Khoddam, S. (2024) ‘Study of survival, metastasis and recurrence rate of breast cancer in comparison with different regimens of endocrine therapy’, *Journal of Pakistan Medical Students*, Available at: <https://jpmsonline.com>
- Kong, X., Moran, M.S., Zhang, N., Haffty, B.G. & Yang, Q. (2021) ‘Meta-analysis confirms achieving pathological complete response after neoadjuvant chemotherapy predicts favourable prognosis for breast cancer patients’, *European Journal of Cancer*, 144, pp. 36–46.
- Kurnia Achmad, Ramli Muchlis, Albar ZA, Panigoro SS, Suyatno. *Kanker Kepala Leher dan Rekonstruksi*. Divisi Bedah Onkologi FKUI/RSCM. Jakarta. 2008.
- Kurnianingrum, L. L., & Tjahjadi, H. (2022). Profil Klinikopatologik Karsinoma Payudara Invasif Metastasis Jauh di Departemen Patologi Anatomi FKUI/RSCM Tahun 2019. *Maj Patol Indones*, 31(3), 359–367. <https://download.garuda.kemdikbud.go.id/article.php?article=2561949&val=15020>
- Langley, R.R. & Fidler, I.J. (2011). The seed and soil hypothesis revisited — the role of tumour-stroma interactions in metastasis to different organs. *International Journal of Cancer*, 128(11), 2527–2535. doi:10.1002/ijc.25975
- Lee, S. J., Go, J., Ahn, B. S., Ahn, J. H., Kim, J. Y., Park, H. S., Kim, S. Il, Park, B.-W., & Park, S. (2023). Lymphovascular invasion is an independent prognostic factor in breast cancer irrespective of axillary node metastasis and molecular subtypes. *Frontiers in Oncology*, 13(November). <https://doi.org/10.3389/fonc.2023.1269971>
- Li, Y., & Ma, L. (2021). Nomograms predict survival of patients with lymph node-positive, luminal a breast cancer. *BMC Cancer*, 21(1), 965. <https://doi.org/10.1186/s12885-021-08642-6>
- Luo, M. et al. (2023) ‘Incidence and risk factors of lymph node metastasis in breast cancer’, *Gland Surgery*, Available at: <https://gs.amegroups.org/article/view/119205>
- Łukasiewicz S., Czezelewski M., Forma A., Baj J., Sitarz R., Stanisławek A. Breast Cancer—Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies—An Updated Review. *Cancers*. 2021;13:4287. doi: 10.3390/cancers13174287. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
- Louise, M., Malene, M., Zaza, U., Mohammed ,F, Kim, F., Annika, L., Jeppe, F., Andreas, K (2022). Prognostic Value of Urokinase-Type Plasminogen Activator Receptor PET/CT in Head and Neck Squamous Cell Carcinomas and Comparison with 18F-FDG PET/CT: A Single-Center Prospective Study. 63(8): 1169–1176.
- Lyndsay N, Nofisat I, Lisa M, Fabrice A, Deborah E. Collyar, Ana M, Elizabeth H, Nicole M, Minetta C, Robert G, Catherine P, Robert C, and Daniel F. Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. 2016; *J Clin Oncol* 34:1134-1150
- Mahmood, N., Mihalciou, C. & Rabbani, S.A., 2018. Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic

- Maiti Das, S., Bhanja Choudhury, K., Mondal, S., & Das, R. (2024). Prognostic significance of Lymph Node Ratio in breast cancer A single institutional retrospective study. *Biomedicine*, 44(4), 406–414. <https://doi.org/10.51248/v44i4.103>
- Märkl, B., Kazik, M., Harbeck, N., Jakubowicz, E., Hoffmann, R., Jung, T., Steinfeld, D., Schenkirsch, G., Schlimok, G., & Oruzio, D. (2019). Impact of uPA/PAI-1 and disseminated cytokeatin-positive cells in breast cancer. *BMC Cancer*, 19(1), 692. <https://doi.org/10.1186/s12885-019-5857-0>
- Mars WM, Zarnegar R, Michalopoulos GK. Activation of hepatocyte growth factor by the plasminogen activators uPA and tPA. *Am J Pathol*. 1993;143:949–58. [PMC free article] [PubMed] [Google Scholar]
- Ma Z, Webb DJ, Jo M, Gonias SL. Endogenously produced urokinase-type plasminogen activator is a major determinant of 1196 Duffy: uPA and PAI-I in Breast Cancer the basal level activated ERK/MAP kinase and prevents apoptosis in MDA-MB-231 breast cancer cells. *J Cell Sci*. 2001;114:3387–96. [PubMed] [Google Scholar]
- Malgorzata, B., Isabell,W., Bahriye,A., Peter, A., Andreas, H., Wolfgang, ., Sabine K., Klaus, P., Gerhard, S., Brigitte, R., Sabine, R, Erich-Franz, S., Tanja, F., Volkmar, Müller (2019). The prognostic relevance of urokinase-type plasminogen activator (uPA) in the blood of patients with metastatic breast cancer, 9: 2318.
- Malmström, P., Bendahl, P.O., Boiesen, P., Brünner, N., Idvall, I. & Fernö, M. (2001) ‘S-phase fraction and urokinase plasminogen activator are better markers for distant recurrences than Nottingham Prognostic Index and histologic grade in a prospective study of premenopausal lymph node-negative breast cancer’, *Journal of Clinical Oncology*, 19(7), pp. 2010–2019. doi:10.1200/JCO.2001.19.7.2010
- Mayrovitz, H.N. (ed.), 2022. *Breast Cancer*. Vol. 1. Brisbane (AU): Exon Publications. Available at: <https://exonpublications.com/index.php/exon/publication/breast-cancer>
- McMahon, B., Kwaan, H.C. & Alessi, D.R. (2008). The plasminogen activator system and cancer. *Nature Reviews Cancer*, 8(4), 226-240. doi:10.1038/nrc2291
- Mustjoki S, Alitalo R, Stephens RW, Vaheri A. Blast cell surface and plasma soluble urokinase receptor in acute leukemia patients: relationship to classification and response to therapy. *Thromb Haemost*. 1999;81:705–10. [PubMed] [Google Scholar]
- Miyake, H., Hara., Ymanaka, K, Gohjo, S., Arakawa, S., Kamidono, S (1999). Elevation of serum levels of urokinase-type plasminogen activator and ist receptor is associated with disease progression and prognosis in patients with prostate cancer ,39(2): 123-9.
- Novrial, D. (2020) ‘Association between axillary lymph node involvement and clinicopathological features of breast cancer among Indonesian women’, *Majalah Kedokteran Indonesia*, Available at: <https://mji.ui.ac.id/journal/index.php/mji/article/view/3306>
- O’Brien M.E., Murray G., Gogoi D., Yusuf A., McCarthy C., Wormald M.R., Casey M., Gabillard-Lefort C., McElvaney N.G., Reeves E.P. A Review of Alpha-1 Antitrypsin Binding Partners for Immune Regulation and Potential Therapeutic Application. *Int. J. Mol. Sci*. 2022;23:2441. doi: 10.3390/ijms23052441. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

Parente, A., Gnangnon, F., Bonny, A., Adjidé, C., Yedomon, G., Mahamat, O., Gbenou, E., Ossei, O., N'Guessan, S., Ouedraogo, A., Sombie, I., Sawadogo, A., Kombate, K., & Kpangon, N. (2025) 'Prognostic factors of breast cancer and survival in Sub-Saharan Africa: a systematic review and meta-analysis', *Breast Cancer Research and Treatment*, 193(1), pp. 45-64. doi:10.1016/j.breastcanres.2025.02.017.

Perou, C.M. et al. (2000) 'Molecular portraits of human breast tumours', *Nature*, 406, pp. 747–752.

Polyak, K. & Metzger, O. (2020) 'Breast cancer progression, metastasis and recurrence: mechanisms and molecular insights', *Nature Reviews Clinical Oncology*, 17(1), pp. 46–60.

Plebani, M., Herszényi, L., Carraro, P., De Paoli, Roveroni, G., Cardin, R., Tulassay, Z., Naccarato, R., Farinati, F. (1997). Urokinase-type plasminogen activator receptor in gastric cancer: tissue expression and prognostic role, 15(4):418-25

Plouet J, Moro F, Bertagnoli S, et al. Extracellular cleavage of the vascular endothelial growth factor 189-amino acid form by urokinase is required for its mitogenic effect. *J Biol Chem*. 1997;272:13390–6.

Philippe, L., Thibault, V., Malick, P., Alexander, K., Alain, P. & Bruno, M. (2006). Prognostic significance of urokinase plasminogen activator and plasminogen activator inhibitor-1 mRNA expression in lymph node and hormone receptor-positive breast cancer. *Journal of Clinical Oncology*, 24(11), 1703–1711. doi:10.1200/JCO.2005.03.4825

Petrelli, F. et al. (2015) 'Prognostic value of Ki-67 in early breast cancer: a systematic review and meta-analysis', *Annals of Oncology*, 26(1), pp. 68–75.

Rahman, H.A., Zaim, S.N.N., Suhaimei, U.S. & Jamain, A.A. (2024) 'Prognostic factors associated with breast cancer-specific survival from 1995 to 2022: A systematic review and meta-analysis of 1,386,663 cases from 30 countries', *Diseases*, 12(6), p. 111. doi:10.3390/diseases12060111.

Rahmi, F., Rikarni, R., & Harminarti, N. (2021). Hubungan Kadar Cancer Antigen 15-3 Serum dengan Metastasis Kanker Payudara. *Jurnal Ilmu Kesehatan Indonesia*, 1(3), 371–378. <https://doi.org/10.25077/jikesi.v1i3.110>

Rakha, E. and Ellis, I. (2018) 'Modern breast cancer classification', *Pathology*, 50(1), pp. 13–22.

Rewcastle, E., Skaland, I., Gudlaugsson, E., Fykse, S. K., Baak, J. P. A., & Janssen, E. A. M. (2024). The Ki67 dilemma: investigating prognostic cut-offs and reproducibility for automated Ki67 scoring in breast cancer. *Breast Cancer Research and Treatment*, 207(1), 1–12. <https://doi.org/10.1007/s10549-024-07352-4>

Stankov, A., Stanojević, G., Spasić, A., et al., 2012. Prognostic factors and recurrence in breast cancer. *Oncology Letters*, 4(6), pp.1223–1228. Available at: <https://pmc.ncbi.nlm.nih.gov/articles/PMC3399427>

Sung, H. H., Ferlay, J., Siegel, P. R., Li, Y., Laversanne, M., Soerjomataram, I., Jemal, A. and Bray, F., 2021. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA: A Cancer Journal for Clinicians*, 71(3), pp.209-249. Available at: <https://doi.org/10.3322/caac.21660>

Susanna, W., Victor B., Martin, C., Peter, J., Hendrica, A., Andrew, P., Bert, A., Hans, M., Cornelis, J., Alexander, L., Cornelis, F. M. Sier (2017). Prognostic Impact of Urokinase Plasminogen Activator Receptor Expression in Pancreatic Cancer: Malignant Versus Stromal Cells, 12: 1177271917715443

Sillen M., Declerck P.J. Targeting PAI-1 in Cardiovascular Disease: Structural Insights Into PAI-1 Functionality and Inhibition. *Front. Cardiovasc. Med.* 2020;7:622473. doi: 10.3389/fcvm.2020.622473. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

Stack M.S., Johnson D.A. Human mast cell tryptase activates single-chain urinary-type plasminogen activator (pro-urokinase) *J. Biol. Chem.* 1994;269:9416–9419. doi: 10.1016/S0021-9258(17)36896-5.

Tincknell G., Piper A.-K., Aghmesheh M., Becker T., Vine K.L., Brungs D., Ranson M. Experimental and Clinical Evidence Supports the Use of Urokinase Plasminogen Activation System Components as Clinically Relevant Biomarkers in Gastroesophageal Adenocarcinoma. *Cancers.* 2021;13:4097. doi: 10.3390/cancers13164097.

To, B., Isaac, D., & Andrechek, E. R. (2020). Studying Lymphatic Metastasis in Breast Cancer: Current Models, Strategies, and Clinical Perspectives. *Journal of Mammary Gland Biology and Neoplasia*, 25(3), 191–203. <https://doi.org/10.1007/s10911-020-09460-5>

Universitas Gadjah Mada, Fakultas Kedokteran, Kesehatan Masyarakat dan Keperawatan. 2022. Registrasi Kanker Berbasis Rumah Sakit Dr Sardjito/ FK-KMK UGM – RKBR Maret 2022: Distribusi Kasus Kanker RSUP Dr Sardjito/ FK-KMK UGM 2008-2019. [online] Available at: <https://canreg.fk.ugm.ac.id/laporan-data/registrasi-kanker-berbasis-rumah-sakit-dr-sardjito-fkkmk-ugm/rkbr-maret-2022>

Vellichirammal, N. N., Tan, Y. De, Xiao, P., Eudy, J., Shats, O., Kelly, D., Desler, M., Cowan, K., & Guda, C. (2023). The mutational landscape of a US Midwestern breast cancer cohort reveals subtype-specific cancer drivers and prognostic markers. *Human Genomics*, 17(1), 1–17. <https://doi.org/10.1186/s40246-023-00511-6>

Völker, H.-U., Weigel, M., Strehl, A., & Frey, L. (2018). Levels of uPA and PAI-1 in breast cancer and its correlation to Ki67-index and results of a 21-multigene-array. *Diagnostic Pathology*, 13(1), 67. <https://doi.org/10.1186/s13000-018-0737-5>

Wang, C., Chen, J., Lv, X., Yun, T., Wang, Y., Meng, N., Li, F., Cao, Y., Fan, N., & Wang, X. (2025). Ki-67—Playing a key role in breast cancer but difficult to apply precisely in the real world. *BMC Cancer*, 25(1), 962. <https://doi.org/10.1186/s12885-025-14374-8>

Weigel, M.T. & Dowsett, M. (2010) ‘Current and emerging biomarkers in breast cancer: prognosis and prediction’, *Endocrine-Related Cancer*, 17(4), pp. R245–R262.

Weiss, A. et al. (2018) ‘Validation study of the AJCC 8th edition prognostic stage for breast cancer’, *JAMA Oncology*, 4(4), pp. 438–447.

Wenjing, C., Andrew, D., Hoffmann, Huiping, L., Xia, L. Organotropism: new insights into molecular mechanisms of breast cancer metastasis. 2018. *npj Precision Oncology* volume 2, Article number: 4

Wilhelm, I., Molnar, J., Fazakas, C., Hasko, J. & Krizbai, I. A. Role of the blood-brain barrier in the formation of brain metastases. 2013. *Int J. Mol. Sci.* 14, 1383–1411 .

Whitelock JM, Murdoch AD, Iozzo RV, Underwood PA. The degradation of human endothelial cell-derived perlecan and release of bound basic fibroblast growth factor by stromelysin, collagenase, plasmin and heparanases. *J Cell Biol.* 1996;271:10079–86.

Yaron J.R., Zhang L., Guo Q., Haydel S.E., Lucas A.R. Fibrinolytic Serine Proteases, Therapeutic Serpins and Inflammation: Fire Dancers and Firestorms. *Front. Cardiovasc. Med.* 2021;8:648947. doi: 10.3389/fcvm.2021.648947.

Youn, I. (2025) 'Prognosis of breast cancer in women in their 20s: Clinical characteristics and outcomes', *Diagnostics*, 15(16), p. 2072.

zhang, M., Deng, H., Hu, R., Chen, F., Dong, S., Zhang, S., Guo, W., Yang, W., & Chen, W. (2025). Patterns and prognostic implications of distant metastasis in breast Cancer based on SEER population data. *Scientific Reports*, 15(1), 26717. <https://doi.org/10.1038/s41598-025-12883-x>

Zhang, Y., Wang, H., Zhao, H., He, X., Wang, Y., & Wang, H. (2024). Prognostic significance and value of further classification of lymphovascular invasion in invasive breast cancer: a retrospective observational study. *Breast Cancer Research and Treatment*, 206(2), 397–410. <https://doi.org/10.1007/s10549-024-07318-6>

Zhou H-M, Bolon I, Nichols A, et al. Over expression of plasminogen activator inhibitor type 2 in basal keratinocytes enhances papilloma formation in transgenic mice. *Cancer Res.* 2002;61:970–6.

Zhong, Y.M. et al. (2022) 'Lympho-vascular invasion impacts the prognosis in breast cancer: a systematic review and meta-analysis', *BMC Cancer*, 22, 919. doi:10.1186/s12885-022-09193-0.

Zhu, H. and Dogan, B.E, "American Joint Committee on Cancer's Staging System for Breast Cancer, Eighth Edition: Summary for Clinicians", *European Journal of Breast Health*, Galenos Publishing House, 1 July, doi: 10.4274/ejbh.galenos.2021.202 1-4-3.